PDCD1 and hepatocellular carcinoma: Specifically, continuous research on immunotherapeutic agents, including PD-1/PD-L1, TMB, ctDNA, microsatellite stability, DNA mismatch repair, neutrophil/lymphocyte ratio, cytokines, and cellular peripheral immune response has shown promising results, especially in patients with HCC resistant to classical chemotherapy [131,132,133].